The New Drug Application (NDA) for the long-acting injectable formulation of rilpivirine + cabotegravir (Janssen and ViiV Healthcare) for patients with HIV-1 infection has been submitted to the Food and Drug Administration (FDA).
This article describes the populations at high risk for HIV infection and reports the results of a collaborative, multifaceted educational intervention designed to reduce the documented disparities related to HIV care and prevention.
Monotherapy with UB-421 antibody, which blocks the HIV virus-binding site on human CD4+ T-cells, maintains viral suppression for up to 16 weeks in HIV-infected persons undergoing analytic treatment interruption.
Investigators sought to categorize hepatitis C virus infections in HIV-positive MSM as either domestically or internationally acquired and evaluate how this classification changed over time.
HIV during the perinatal period in the US have declined over recent decades, but its prevalence rates in female adults and adolescents continues to rise.
ViiV Healthcare announced positive 48-week data from the phase 3 ATLAS (N=616) and FLAIR (N=566) studies evaluating a long-acting injectable formulation of cabotegravir + rilpivirine in patients with HIV-1 infection.
